Cambridge, 26 October 2026: SolasCure has been awarded a grant by the Medical Technology Enterprise Consortium (MTEC), funded by the US Defense Health Agency, to develop an enhanced Aurase Wound product for the prevention of infection in battlefield wounds treated in austere settings.

The two-year project has a total value of $1.2 million, partially funded by MTEC and the Defense Health Agency.

The programme will develop a formulation combining tarumase, SolasCure's proprietary enzyme, with a broad-spectrum antimicrobial agent. The objective is prophylactic prevention of infection in contaminated trauma wounds at or near the point of injury, in environments where surgical care is not available and evacuation may be delayed.

Tarumase is a recombinant fibrinolytic enzyme that selectively degrades non-viable tissue. It is the active pharmaceutical ingredient in Aurase Wound Gel, SolasCure's investigational product for chronic wounds.

The MTEC programme applies the same ingredient, produced through the same manufacturing process, to a different setting. Combining tarumase with a broad-spectrum antimicrobial agent is intended to produce a single product that can be applied at or near the point of injury by personnel without specialist training.

"This award allows us to apply our innovative enzyme to a setting where the need for rapid, safe wound care is acute. We are grateful to MTEC and the Defense Health Agency for their support." - Lee Harle, CEO, SolasCure

About MTEC

The Medical Technology Enterprise Consortium is a biomedical technology consortium working in partnership with the US Department of Defense to accelerate the development of medical solutions for the armed forces.

About SolasCure

SolasCure is a biotechnology company based in Cambridge, United Kingdom, developing enzymatic therapies for wound care. Its lead product, Aurase Wound Gel, is an investigational dual-action therapy that debrides chronic wounds and actively promotes healing at the same time, without pain, anaesthesia or a surgeon.

Effort sponsored by the Government under Other Transaction Number W81XWH-15-9-0001. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon.

The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.